LENZING |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-.--% | -.--% |
| 05-08 | Transcript : Lenzing Aktiengesellschaft, Q1 2024 Earnings Call, May 08, 2024 | |
| 05-03 | Lenzing Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Specialty Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -.--% | 1.5B | - | ||
| +20.12% | 5.52B | C | ||
| +0.86% | 5.1B | C- | ||
| +1.63% | 3.78B | C | ||
| +5.14% | 2.3B | - | - | |
| +4.91% | 1.68B | B+ | ||
| -2.04% | 1.09B | - | D+ | |
| +4.28% | 1.06B | - | ||
| +36.51% | 808M | - | - | |
| -22.09% | 482M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LNZ Stock
- 0NCV Stock
- Ratings Lenzing
